Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GALR2 | O43603 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560543 | 0.92 | PDGFRB (0.51) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1770763 | 0.87 | PDGFRB (0.55) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL16352780 | 0.87 | PDGFRB (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1721669 | 0.86 | PDGFRB (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL22833404 | 0.86 | SIRT6 (0.44) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL23094629 | 0.86 | PDGFRB (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL17560534 | 0.86 | POLB (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL22836429 | 0.84 | PDGFRB (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL15122891 | 0.84 | PDGFRB (0.45) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL25487018 | 0.84 | PDGFRB (0.51) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116648250-B | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2025-06-13 | — | — | CN | disclosed |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| EP-4269395-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269395-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648250-A | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2023-08-25 | — | — | CN | disclosed |
| CN-116535412-A | Polycyclic compounds as SOS1 inhibitors | 昆药集团股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022139304-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | 한미약품 주식회사 | 2022-06-30 | — | — | WO | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | PDGFRB 949/4885FGFR1 2336/4885PDGFRA 472/4885 |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | SOS1, RASGRP1, RAC1 | PDGFRB 3461/4885FGFR1 1918/4885PDGFRA 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.